COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Named one of Boston Business Journal’s 2020 Best Places to Work

Collegium Pharmaceutical Named one of Boston Business Journal’s 2020 Best Places to Work

STOUGHTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of Boston Business Journal’s 2020 Best Places to Work.

“We are honored to be recognized by the Boston Business Journal, and importantly, by our employees, as one of Boston’s best places to work,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “At Collegium, we are fortunate to have a remarkably talented team of people who are committed to upholding our core values and dedicated to our mission of becoming the leader in responsible pain management.”

The Boston Business Journal’s Best Places to Work program recognizes companies that have built extraordinary work environments for their people. This year, Boston Business Journal recognized companies ranging in size and industry. The rankings are determined by employees’ responses to survey questions which focus on work environment, work-life balance, job satisfaction, advancement opportunities, management, compensation and benefits.

For more information on career opportunities at Collegium, and to learn more about our mission and core values, please visit the careers portion of our company website at .

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the company’s website at .

Contact:

Alex Dasalla

EN
17/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 13,976 shares at 34.924USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

 PRESS RELEASE

Collegium to Present New Real-World Data at PainConnect 2026

Collegium to Present New Real-World Data at PainConnect 2026 STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, taking place in Salt Lake City, Utah from March 5-8, 2026. The presentations highlight real-world clinical insights from Collegium’s pain portfolio and reflect the Company’s continued focus on generating evidence that helps inform everyday practice. “U...

 PRESS RELEASE

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Em...

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community – Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are often part of living with ADHD, including the importance of talking to a doctor and finding an individualized treatment plan –          Credit: Ashley Osborn STOUGHTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasd...

 PRESS RELEASE

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026Miami, FL Jefferies Biotech on the Beach SummitTuesday, March 10, 2026Miami, FL The Citizens Life Sciences ConferenceTuesday, March 10, 2026Miami, FL Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ETMiami, FL A live webcast of the fire...

 PRESS RELEASE

Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results

Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results – Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash Equivalents...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch